Glycyrrhetinic acid modified MOFs for the treatment of liver cancer.

Li, Li; Han, Shasha; Yang, Chun; Liu, Lin; Zhao, Sengqun; Wang, Xiaofang; Liu, Bingmi; Pan, Hao; Liu, Yu

Li, Li; Han, Shasha; Yang, Chun; Liu, Lin; Zhao, Sengqun; Wang, Xiaofang; Liu, Bingmi; Pan, Hao; Liu, Yu.

Affiliation

Li L; School of Pharmacy, Liaoning University, Shenyang 110036, People's Republic of China. Liaoning Key Laboratory of New Drug Research & Development, Shenyang 110036, People's Republic of China.

Nanotechnology ; 31(32): 325602, 2020 Aug 07.

Article in En | MEDLINE | ID: mdl-32320964

Subject(s)

Antimetabolites, Antineoplastic/administration & dosage; Fluorouracil/administration & dosage; Glycyrrhetinic Acid/chemistry; Liver Neoplasms/drug therapy; Animals; Antimetabolites, Antineoplastic/chemistry; Antimetabolites, Antineoplastic/pharmacokinetics; Cell Proliferation/drug effects; Cell Survival/drug effects; Fluorouracil/chemistry; Fluorouracil/pharmacokinetics; Hep G2 Cells; Humans; Metal Nanoparticles; Mice; Particle Size; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fluorouracil / Glycyrrhetinic Acid / Liver Neoplasms / Antimetabolites, Antineoplastic Limits: Animals / Humans Language: En Journal: Nanotechnology Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google